All Stories
Follow
Subscribe to Mologen AG

Mologen AG

ots Ad hoc-Service: Mologen Holding AG <DE0006637200> Mologen files patent application for gene-modified cell vaccine

Berlin (ots Ad hoc-Service) -

Ad hoc-announcement edited and sent by DGAP. The sender is solely
responsible for the contents of this announcement.
Mologen Holding AG, Berlin, Germany
has developed a gene-modified cell vaccine for the treatment of
kidney cancer. The company has filed a patent application for the
vaccine which consists of several-fold gene-modified tumor cells. The
vaccine has been tested in a clinical phase I/II trial and the
results have been reported in the February issue of the journal Human
Gene Therapy.
The vaccine had no adverse effects, and manufacture and
application of the vaccine were safe and reproducible. Following
treatment, relevant clinical parameters improved in five out of the
ten patients. One patient had a complete remission. No certain
conclusions on efficacy can be drawn at this time, but the results
suggest that the gene-modified cell vaccine can benefit advanced
tumor patients with a large metastatic tumor burden.
Mologen considers these findings as a confirmation of safety and
efficacy of its MIDGE vector technology, which was developed and
patented by Mologen for the use of genetic information in the
treatment and prevention of diseases. Mologen is currently preparing
for efficacy testing of the gene-modified cell vaccine in a clinical
trial of phase III.

Contact:

info@mologen.com

www.mologen.com

Tel.: 841 788-13, Fax -50

End of message
Internet: http://recherche.newsaktuell.de

Original content of: Mologen AG, transmitted by news aktuell

More stories: Mologen AG
More stories: Mologen AG
  • 21.12.2000 – 07:30

    ots Ad hoc-Service: Mologen Holding AG <DE0006637200>

    Mitteilung gemäß Paragraph 15 WpHG, übermittelt von der DGAP Für den Inhalt ist allein der Emittent verantwortlich Berlin (ots Ad hoc-Service) - MIDGE Patent europaweit erteilt Die Mologen Holding AG teilt mit, dass das Europäische Patentamt das Basispatent zur MIDGE Technologie erteilt hat. Das MIDGE Patent wird die Nummer EP0941318 haben. Das Patent umfasst das Design der Vektoren, die Mologen zur ...

  • 21.12.2000 – 07:29

    ots Ad hoc-Service: Mologen Holding AG <DE0006637200>

    Berlin (ots Ad hoc-Service) - MIDGE Patent granted by European Patent Office Mologcn announces the issuance of the basic patent covering the MIDGE minimalistic vector technology. The patent will be issued for Europe as EP0941318 and covers the design principle of Mologen's vectors used for genetic vaccination and gene therapy. Another patent covering the vector systems production has been issued in Germany, and ...